
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Alirocumab (Praluent) is a PCSK9 inhibitor for the treatment of heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.
Medication Pearl of the Day: Alirocumab (Praluent)
Indication: Alirocumab(Praluent) is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-cholesterol (LDL-C).
Insight:
Sources:





